tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

China Resources Pharmaceutical Reports H1 2025 Financial Results

Story Highlights
China Resources Pharmaceutical Reports H1 2025 Financial Results

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) just unveiled an update.

China Resources Pharmaceutical Group Ltd. reported its unaudited interim results for the first half of 2025, showing a slight increase in revenue to RMB 131.87 billion compared to the previous year. Despite the revenue growth, the company’s net profit decreased to RMB 5.05 billion, attributed to higher selling and distribution expenses, and other losses. The results highlight challenges in maintaining profitability amidst rising operational costs, which could impact the company’s market positioning and stakeholder confidence.

The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.

More about China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the production and distribution of pharmaceutical products. The company is known for its comprehensive range of healthcare solutions, catering to both domestic and international markets.

Average Trading Volume: 12,295,656

Technical Sentiment Signal: Sell

Current Market Cap: HK$32.23B

Learn more about 3320 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1